Statement: the primary trial and the secondary trial both report cases of confusion in their patient cohorts.
Primary_evidence: Adverse Events 1:   Total: 4/33 (12.12%)   Diarrhea 1/33 (3.03%)   Intracranial hemorrhage 1/33 (3.03%)   Ischemia cerebrovascular 1/33 (3.03%)   Confusion 1/33 (3.03%)   Skin disorder 1/33 (3.03%)
Secondary_evidence: Adverse Events 1:   Total: 5/11 (45.45%)   Nausea 1/11 (9.09%)   Vomiting 1/11 (9.09%)   Fever 1/11 (9.09%)   skin infection  [1]1/11 (9.09%)   Hip fracture 0/11 (0.00%)   Confusion 1/11 (9.09%) Adverse Events 2:   Total: 1/12 (8.33%)   Nausea 0/12 (0.00%)   Vomiting 0/12 (0.00%)   Fever 0/12 (0.00%)   skin infection  [1]0/12 (0.00%)   Hip fracture 1/12 (8.33%)   Confusion 0/12 (0.00%)